XML 21 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income attributable to Myriad Genetics, Inc. stockholders $ 4.6 $ 133.3 [1] $ 17.4 [1]
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 73.0 54.4 [1] 48.3 [1]
Non-cash interest expense 0.4 0.2 [1] 0.4 [1]
Gain on disposition of assets (0.9) (0.2) [1] (0.3) [1]
Share-based compensation expense 33.5 27.1 [1] 29.9 [1]
Impairment of cost basis investment [1]     2.4
Loss on extinguishment of debt [1]     1.3
Deferred income taxes 18.6 (23.5) [1] 0.8 [1]
Unrecognized tax benefits (5.5) (0.3) [1] 1.2 [1]
Change in fair value of contingent consideration (1.4) (60.9) [1] (0.8) [1]
Payment of contingent consideration (1.5) (22.7) [1]  
Changes in assets and liabilities:      
Prepaid expenses (3.2) 3.3 [1] 7.8 [1]
Trade accounts receivable (18.2) (9.1) [1] 0.5 [1]
Other receivables (0.7) 1.1 [1] (4.0) [1]
Inventory 8.0 7.9 [1] (1.2) [1]
Prepaid taxes (25.1)   3.4 [1]
Accounts payable 1.1 4.0 [1] (3.0) [1]
Accrued liabilities 1.5 1.4 [1] 1.2 [1]
Deferred revenue (0.5) (0.1) [1] 0.9 [1]
Net cash provided by operating activities 83.7 115.9 [1] 106.2 [1]
CASH FLOWS FROM INVESTING ACTIVITIES      
Capital expenditures (8.6) (8.4) [1] (6.1) [1]
Acquisitions, net of cash acquired (278.5)   (216.1) [1]
Sale of cost basis investment [1]     2.6
Purchases of marketable investment securities (78.5) (80.9) [1] (87.5) [1]
Proceeds from maturities and sales of marketable investment securities 79.2 77.7 [1] 160.8 [1]
Net cash used in investing activities (286.4) (11.6) [1] (146.3) [1]
CASH FLOWS FROM FINANCING ACTIVITIES:      
Net proceeds from common stock issued under share-based compensation plans 8.7 36.9 [1] 6.0 [1]
Proceeds from revolving credit facility 340.0 53.0 [1] 204.0 [1]
Repayment of revolving credit facility (115.0) (143.0) [1] (105.0) [1]
Net proceeds from term loan [1]     199.0
Repayment of term loan [1]     (200.0)
Payment of contingent consideration recognized at acquisition [1]   (42.4)  
Fees associated with restructure of debt (1.4)   (0.6) [1]
Repurchase and retirement of common stock (50.0)   (31.6) [1]
Proceeds from non-controlling interest [1]   0.5  
Net cash provided by (used in) financing activities 182.3 (95.0) [1] 71.8 [1]
Effect of foreign exchange rates on cash and cash equivalents 2.7 (0.8) [1] 2.2 [1]
Net increase (decrease) in cash and cash equivalents (17.7) 8.5 [1] 33.9 [1]
Cash and cash equivalents at beginning of year [1] 110.9 102.4 68.5
Cash and cash equivalents at end of year $ 93.2 $ 110.9 [1] $ 102.4 [1]
[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements of this report for additional information.